TMCnet News
DeuteRx Announces $2.8 Million of Seed Financing to Support Advancement of DRX-065 for the Treatment of Adrenoleukodystrophy (ALD)DeuteRx LLC announced today the initial closing of a seed financing that will total approximately $2.8 million. DeuteRx is a research and development-focused biotechnology company dedicated to improving racemic small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications. The funding supports the advancement of DeuteRx's lead program, DRX-065, into human clinical trials for the treatment of adrenoleukodystrophy (ALD). "This funding will allow us to aggressively pursue our lead program for ALD, a monogenic orphan disease for which there is no approved therapy," said Sheila DeWitt, Ph.D., President and Chief Executive Officer of DeuteRx. "The preclinical results that DeuteRx has obtained with DRX-065, the stabilized R-enantiomer of pioglitazone, have changed the interpretation of more than 25 years of R&D efforts, which define the mechanism of action for pioglitazone and related thiazolidinediones (TZDs) as PPAR? agonists," said Dr. Lex Van der Ploeg, advisor to DeuteRx. "DeuteRx's unique ability to study stabilized, single enantiomers has revealed surprising differences in the pharmacological properties of each enantiomer of pioglitazone. DRX-065 has the potential to be a disease-modifying and reversing treatment for ALD patients, without the side effects caused by S-pioglitazone." Dr. DeWitt will be presenting preclinical results obtained with DRX-065 and their relevance for the treatment of non-alcoholic steatohepatitis (NASH) at the American Association for the Study of Liver Diseases' Liver Meeting on November 16, 2015, in San Francisco.
About Adrenoleukodystrophy (ALD) The incidence of ALD has been estimated to be 1:17.000 newborns. ALD can manifest itself in children, where death or permanent disability occurs within two to five years of diagnosis. The adult form of ALD is known as adrenomyeloneuropathy (AMN) and the average age of onset is 28. Cerebral involvement occurs in 30 to 50 percent of AMN patients and leads to a poorer prognosis, including severe disability and death, when compared to patients without cerebral involvement. There are currently no approved therapies for ALD or AMN. The most widely used treatment option is the dietary supplement, Lorenzo's oil, which is thought to aid in the normalization of VLCFA levels. However, this oil does not seem to alter the progression of the disease once the brain is involved. In 2013, L. Morató, et al. (Brain. 2013, 136(Pt 8), 2432-2443) reported that pioglitazone, a drug approved for the treatment of Type 2 diabetes, halted the locomotor disability and axonal damage in a murine model of ALD. A phase 2 trial of pioglitazone in AMN patients by the lead author, Dr. Aurora Pujol, is ongoing in Spain.
About DRX-065
About DeuteRx LLC DeuteRx is a Boston-based biotechnology company founded in December 2012 as a spin-out company from Deuteria Pharmaceuticals Inc. Deuteria Pharmaceuticals was sold to a major biopharmaceutical company in December 2012.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150930005350/en/ |